Please assess the completion status of the following clinical trial:

Trial Title: Bi-weekly Cetuximab Combined With 5-fluorouracil/Leucovorin/Oxaliplatin (FOLFOX-6) in Metastatic Colorectal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven metastatic colorectal cancer~* Molecular test showing no mutation in the k-ras gene of colorectal carcinoma cells~* Male and female subjects ≥ 18 years of age~* 1st occurrence of metastatic disease (not curatively resectable)~* Life expectancy ≥ 12 weeks~* Presence of at least 1 bi-dimensionally measurable index lesion (not in an irradiated area)~* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 at study entry~* Adequate bone marrow reserve:~leucocytes ≥ 3.0 x 109/l with neutrophils ≥ 1.5 x 109/l, platelets ≥ 100 x 109/l, haemoglobin ≥ 6.21 mmol/l (10 g/dl)~* Aspartate-aminotransferase (ASAT) and alanine-aminotransferase (ALAT) ≤ 2.5 x upper reference range, in case of liver metastasis ≤ 5 x upper reference range~* Serum creatinine ≤ 1.5 x upper reference range~* Bilirubin ≤ 1.5 x upper reference range~* Negative pregnancy test for female and effective contraception for both male and female subjects if the risk of conception exists~* Signed written informed consent~Exclusion Criteria:~* Evidence for a mutation of the k-ras gene in the colorectal carcinoma cells~* Previous exposure to epidermal growth factor receptor-targeting therapy~* Prior chemotherapy for metastatic disease~* Prior oxaliplatin based adjuvant chemotherapy or \< 6 months after end of adjuvant treatment~* Other previous malignancy with exception of a history of a previous curatively treated basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix~* Radiotherapy, surgery (excluding prior diagnostic biopsy) or any investigational drug in the 30 days before registration~* Concurrent chronic systemic immune therapy or hormone therapy not indicated in this study protocol~* Creatinine clearance \< 30 ml/min~* Known hypersensitivity reaction to any of the components of study treatment~* Pregnancy (absence to be confirmed by ß-human chorionic gonadotropin (hCG) test) or lactation period~* Clinically relevant coronary artery disease, history of myocardial infarction in the last 12 months, or high risk of uncontrolled arrhythmia~* Acute or sub-acute intestinal occlusion or history of inflammatory bowel disease~* Brain metastasis (known or suspected)~* Medical or psychological conditions that would not permit the subject to complete the study or sign informed consent~* Known alcohol or drug abuse~* Participation in another clinical study within the 30 days before registration~* Peripheral neuropathy \> grade 1~* Significant disease which, in the investigator's opinion, would exclude the patient from the study~* Legal incapacity or limited legal capacity

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cetuximab + Folfox-6-regime (Type: EXPERIMENTAL): Cetuximab 500 mg/m² administered as an intravenous infusion over 120 minutes on day 1 every 2 weeks. Combined with the following FOLFOX-6-regime:~Oxaliplatin 85 mg/m² i.v. for 2 h on day 1, Folinic acid 400 mg/m² i.v. for 2 h concurrently with Oxaliplatin on day 1, Fluorouracil 400 mg/m² i.v. bolus after Folinic Acid on day 1, followed by Fluorouracil 2400 mg/m² i.v. over 46 h.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete